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Strong evidence suggests that lipid metabolism (LM) has an essential role in tumor growth
to support special energetic and structural requirements of tumor cells. Recently, overex-
pression of LM-related genes, apolipoproteins related to metabolic syndrome, and ACSL/
SCD network involved in fatty acid activation have been proposed as prognostic markers of
colon cancer (CC). Furthermore, activation of this latter lipid network has been recently
demonstrated to confer invasive and stem cell properties to tumor cells promoting tumor
aggressiveness and patient relapse. With the aim of elucidating whether any genetic varia-
tion within these genes could influence basal expression levels and consequent susceptibil-
ity to relapse, we genotype, in 284 CC patients, 57 polymorphisms located in the 7 genes of
these lipid networks previously associated with worse clinical outcome of CC patients
(ABCA1, ACSL1, AGPAT1, APOA2, APOC1, APOC2 and SCD), some of them related to
CC aggressiveness. After adjusting with clinical confounding factors and multiple compari-
sons, an association between genotype and disease-free survival (DFS) was shown for
rs8086 in 3’-UTR of ACSL1 gene (HR 3.08; 95% CI 1.69–5.63; adjusted p = 0.046). Further-
more, the risk T/T genotype had significantly higher ACSL1 gene expression levels than
patients carrying C/T or C/C genotype (means = 5.34; 3.73; 2.37 respectively; p-value
(ANOVA) = 0.019), suggesting a functional role of this variant. Thus, we have identified a
“risk genotype” of ACSL1 gene that confers constitutive high levels of the enzyme, which is
involved in the activation of fatty acids through conversion to acyl-CoA and has been
recently related to increased invasiveness of tumor cells. These results suggest that rs8086
of ACSL1 could be a promising prognostic marker in CC patients, reinforcing the relevance
of LM in the progression of CC.
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Introduction
Colorectal cancer (CRC [MIM: 114500]) is one of the most common neoplasms worldwide,
and represents the third most frequent cancer in men (746 000 cases, 10%) and the second in
women (614 000 cases, 9.2%). In Europe CRC represents the second cause of cancer deaths,
estimating 113 000 deaths in men (11.6%) and 101 000 in women (13%), and only behind lung
cancer (26.1%) and breast cancer (16.8%) respectively [1].
The pathogenesis of CRC is extremely complex and implicates sequential genetic and epige-
netic mechanisms, which in many cases remain to be elucidated. Lifestyle factors, nutrition,
environment, as well as genetic events have been associated with the causality of CRC and sur-
vival of patients after diagnosis of CRC [2]. In this sense, obesity has been linked to higher risk
of developing CRC [3–5] and several studies have shown an increased risk of about 1.5 to 3
times, and found a 3% increase in the risk of CRC per 1 unit increase in the body mass index
[5, 6]. Epidemiological studies have reported that in Europe around 11% of CRC cases have
been attributed to overweight and obesity. Thus, obesity is associated with worse cancer out-
come, including recurrence of the primary cancer or mortality [7]. Indeed, obesity has been
significantly associated with CC recurrence and death in patients with curatively resected stage
II and III cancers treated with adjuvant chemotherapy, and this association was more evident
in patients who had severe obesity compared with normal-weight patients. Furthermore, obe-
sity compared with normal-body weight was significantly associated with an increased number
of lymph node metastases, an established worse prognostic factor in CC [8, 9].
In this sense, we have recently reported that several genes traditionally linked to metabolic
syndrome and obesity such as apolipoproteins A2, C1 or C2 play also a relevant role in CC
progression, reporting for the first time a genetic link among these diseases. Furthermore, we
have found that LM activation specifically through Acyl-CoA synthetase/ Stearoyl-CoA desa-
turase ACSL/SCD network, is associated to CC patient relapse due to phenotypic plasticity
associated to this metabolic reprogramming [10–12].
Surgical resection is the only curative treatment modality for localized CC (stage I-III), and
adjuvant chemotherapy is recommended for high-risk stage II and all stage III tumors [13].
While adjuvant chemotherapy is standard for stage III CC patients because reduces risk of
recurrence and prolongs DFS [13] its use in stage II CC patients is controversial [14]. How-
ever, even with adjuvant chemotherapy, 20%-30% of high-risk stage II and 30%-40% of stage
III patients relapse within 5 years [13]. In current clinical practice, the majority of these inter-
mediate stage CC patients receive adjuvant treatment unnecessarily, either because they were
cured by surgery alone or because they will relapse despite adjuvant treatment [14]. Conse-
quently, it is essential to identify markers that might classify patients who will benefit from
adjuvant therapy, and avoid the toxic and unnecessary chemotherapy in patients who will
relapse despite adjuvant treatment. In this regard, in our recent analysis of LM alterations asso-
ciated to CC progression, we identify a gene expression signature of 4 LM-related genes (Colo-
LipidGene) with a strongly marked role in stage II CC patients prognosis [11]. We observed
that the combined activation of lipid transport through ABCA1 (ATP-Binding Cassette Sub-
family-A Member 1 (ABCA1 [MIM: +600046]), lipid activation through ACSL1 and AGPAT1
(Acyl-CoA Synthetase Long Chain Family, Member 1 (ACSL1 [MIM: 152425]), 1-Acylgly-
cerol-3-Phosphate O-Acyltransferase 1 (AGPAT1 [MIM: 603099]) and lipid-related toxicity
drainage through SCD (Stearoyl-Coa Desaturase (SCD [MIM: 604031]) might confer an ener-
getic advantage to the tumoral cell resulting in the promotion of tumor progression and
relapse [10–12].
Proceeding with this line of research, and with the aim of identifying whether any genetic
alteration might be related to overexpression of these enzymes and therefore constitute a
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biomarker of LM-related alterations, we analyzed in stage II and III CC patients the main poly-
morphisms within these genes previously identified as potential promoters of the energetic
advantage associated with worse clinical outcome of CC patients [11, 12].
Materials and Methods
Subjects
This retrospective study consisted of a cohort of 308 stage II and III CC patients who had
undergone surgery between 2000 and 2008 in La Paz University Hospital, from which 8 were
eliminated due to low quantity of the tumor sample. CC patients were clinically diagnosed
based on histopathological criteria by AJCC/UICC and were classified following the clinical
risk criteria of the American Society of Clinical Oncology (ASCO), and were randomly
selected for this study. Eligibility required histologically confirmed Stage II or III AJCC/UICC
primary colorectal cancer, long-term follow-up among survivors (>3 years) and age 18,
completely resected colon adenocarcinoma located at15 cm of the anal verge as determined
by endoscopy or above the peritoneal reflection in the surgical resection. Additional eligibility
criteria included good quality of RNA sample. Patients who died within 30 days after surgery,
patients with incompletely excised tumor, mixed histological features or other cancers in the
previous 5 years were ineligible for this study. Tumor samples were obtained with the approval
of The Ethics Committee for Clinical Research (CEIC) of La Paz University Hospital (Madrid)
(approval reference: HULP-PI-1452) and were stored embedded in paraffin. All subjects gave
their written informed consent to participate in the study and were previously included in
gene expression association studies [11, 12].
Clinical data for the CC cases were retrieved from the registry managed by oncologists of
La Paz University Hospital (Table 1).
Additionally, we included in this study 40 samples of healthy human colon tissues that were
obtained from apparently healthy tissues adjacent to tumors from the patients.
Candidate genes and SNP selection
Genes were selected according to their key role in the LM and their association in CC progno-
sis on the basis of previously published gene expression studies [11, 12]. Genetic variants were
chosen from the set of common single-nucleotide polymorphisms (SNPs) genotyped in the
Caucasian population sample of the HapMap project (Data Release 28/phaseII+III August10,
on National Center for Biotechnology Information B36 assembly, dbSNP build 126). The soft-
ware Haploview version 4.2 (Broad Institute of MIT and Harvard) was used to evaluated hap-
lotype blocks in each gene, as well as to select haplotype tagging SNPs (htSNPs), capturing the
variations of all SNP alleles within the gene region with r2 threshold 0.8. The gene region was
defined as an extent of genomic DNA + 5 kb approximately upstream and downstream from
the first base of the first known exon to the last base of the last known exon. SNPs were selected
with main emphasis on their tagging characteristics and on their location (non-synonymous
mutation located in exons or functional SNPs located in putative gene regulatory regions, such
as promoter regions, 5’ or 3’UTR). We delimited the selection to markers, which in HapMap
had a minor allelic frequency (MAF) of at least 5% (with rare and justified exceptions). For
TaqMan1 SNP Genotyping Assays, we further selected SNPs with low probability of genotyp-
ing failure.
Allele frequency and location for each SNP was based on dbSNP (National Center for Bio-
technology Information, National Institutes of Health).
Following these criteria, a total of 57 SNPs in 7 genes were selected (Table 2). Eighteen out
of the 57 SNPs selected in this study (31,6%) were functional SNPs (located in 5´ near gene, 5’-
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Table 1. Clinical characteristics of stage II and III CC patients (n = 284).
Variable CC Stage II (n = 157) CC Stage III (n = 127)
Number (%) Number (%)
Sex
Male 92 (58.6) 66 (51.97)
Female 65 (41.4) 61 (48.03)
Age (years)
Mean (SD) 67.55 (12.2) 64.34 (11.73)
Range 23–92 23–85
pT category
1–3 107 (68.15) 98 (77.17)
4 50 (31.85) 29 (22.83)
pN category
0 157 (100) 0
1 0 87 (68.5)
2 0 40 (31.5)
Stage
II 157 (100) 0
III 0 127 (100)
Lymph Nodes Resected
12 80 (52.3) 39 (30.72)
>12 73 (47.68) 88 (69.3)
Unknown 4 0
Tumour site
Cecum and Ileocecal Valve 11 (7.05) 19 (14.96)
Acending colon and Hepatic flexure 46 (29.49) 19 (14.96)
Transverse colon 10 (6.41) 12 (9.45)
Splenic flexure and Descending colon 19 (12.18) 17 (13.39)
Sigmoid colon and rectosigmoid junction 70 (44.87) 60 (47.24)
Unknown 1 0
Differentiation Grades
Well 12 (7.64) 8 (6.3)
Moderately 130 (82.8) 99 (77.95)
Poor 15 (9.55) 20 (15.75)
Vascular invasion
Yes 42 (27.1) 56 (44.09)
No 113 (72.9) 71 (55.91)
Unknown 2 0
Neuronal invasion
Yes 28 (18.06) 50 (39.37)
No 127 (81.94) 77 (60.63)
Unknown 2 0
Peritoneal perforation or obstruction
Yes 44 (28.03) 37 (29.13)
No 113 (71.97) 90 (70.87)
Adjuvant chemotherapy
5-FU/LV or XELOX or FOLFOX 98 (62.42) 127 (100)
No treatment 59 (37.58) 0
Disease-free survival
Relapses 29 (18.47) 46 (36.22)
Overall survival
Exitus 17 (10.9) 24 (18.9)
SD, standard deviation; 5-FU/LV, 5-Fluorouracil-Leucovorin; XELOX, Capecitabine plus Oxaliplatin;
FOLFOX, Oxaliplatin plus 5-FU/LV.
doi:10.1371/journal.pone.0168423.t001
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Table 2. Location and SNP type of investigated polymorphisms.
Assay ID dbSNP Gene Symbol NCBI Assembly
Location
SNP Type
C__11453334_10 rs5082 (5’ near APOA2
gene)
ch. 1: 161193683 5’ near gene; Intron; Transition Substitution
C____904974_10 rs439401 (near APOC1 gene) ch. 19: 45414451 Intergenic; Transition Substitution; LD with rs584007 (5’ near
gene)
C__11466277_30 rs1064725 APOC1 ch. 19: 45422561 3’-UTR; Transversion Substitution
C__15880051_10 rs2288911 APOC2 ch. 19: 45449284 5’-UTR; Transversion Substitution
C___1345738_10 rs3870747 SCD ch. 10: 102113679 Intron; Transition Substitution; LD with rs11557927 (3’ UTR)
C___1345731_10 rs508384 (near SCD gene) ch. 10: 102124761 Intron; Transversion Substitution; LD with rs7849 (3’ UTR)
C____623412_10 rs599961 SCD ch. 10: 102117207 Intron; Transversion Substitution; LD with rs560792 (3’ UTR)
C___8734182_10 rs1502593 SCD ch. 10: 102109202 Intron; Transition Substitution
C__44899326_10 rs2234970 SCD ch. 10: 102116311 Missense Mutation; Transversion Substitution
C__31980235_10 rs11190483 SCD ch. 10: 102113649 Intron; Transition Substitution
C___9260122_10 rs522951 SCD ch. 10: 102110901 Intron; Transversion Substitution
C___1345737_10 rs3829160 SCD ch. 10: 102115007 Intron; Transition Substitution
C___8242163_10 rs8086 ACSL1 ch. 4: 185677421 3’-UTR; Transition Substitution
C__29419656_10 rs4069938 ACSL1 ch. 4: 185700776 Intron; Transversion Substitution
C___1170092_10 rs4862417 ACSL1 ch. 4: 185690601 Intron; Transition Substitution; LD with rs2292899 (3’ UTR)
C___1170045_10 rs12503643 ACSL1 ch. 4: 185746088 Intron; Transversion Substitution
C__30469648_10 rs6552828 ACSL1 ch. 4: 185725416 Intron; Transition Substitution
C___8242164_10 rs1056896 ACSL1 ch. 4: 185677363 3’-UTR; Transition Substitution
C__11785598_10 rs12644905 (3’ near ACSL1
gene)
ch. 4: 185676683 3’ near gene; Intron; Transition Substitution
C___1170050_1_ rs2280297 ACSL1 ch. 4: 185736113 Intron; Transversion Substitution
C___1170082_10 rs7681334 ACSL1 ch. 4: 185710859 Intron; Transition Substitution
C___1170059_10 rs13112568 ACSL1 ch. 4: 185730299 Intron; Transition Substitution
C___1170066_10 rs11936062 ACSL1 ch. 4: 185721370 Intron; Transversion Substitution
C___1170097_10 rs11727009 ACSL1 ch. 4: 185687863 Intragenic; Transition Substitution; Silent Mutation
C__15931315_10 rs2777786 ABCA1 ch. 9: 107661561 Intron; Transversion Substitution
C___2741051_1_ rs2230806 ABCA1 ch. 9: 107620867 Missense Mutation; Transition Substitution
C___2741083_1_ rs2066714 ABCA1 ch. 9: 107586753 Missense Mutation; Transition Substitution; Silent Mutation
C___2741104_1_ rs2230808 ABCA1 ch. 9: 107562804 Missense Mutation; Transition Substitution
C____500971_10 rs2472449 ABCA1 ch. 9: 107604197 Intron; Transversion Substitution
C___2741081_20 rs2066715 ABCA1 ch. 9: 107588033 Missense Mutation; Transition Substitution
C__31952217_10 rs4149338 ABCA1 ch. 9: 107545903 3’-UTR; Transition Substitution
C__16235603_10 rs2472496 (near ABCA1 gene) ch. 9: 107695353 Intergenic; Transition Substitution
C__15849583_20 rs2740486 ABCA1 ch. 9: 107666513 Intron; Transversion Substitution
C__11720789_10 rs2066718 ABCA1 ch. 9: 107589255 Missense Mutation; Transition Substitution
C__16235415_10 rs2246293 (5’ near ABCA1
gene)
ch. 9: 107690838 5’ near gene; intron; Transversion Substitution
C___2741115_10 rs363717 ABCA1 ch. 9: 107544700 3’-UTR; Transition Substitution
C___1139523_20 rs2472377 ABCA1 ch. 9: 107687104 Intron; Transition Substitution
C__29854619_10 rs4149340 ABCA1 ch. 9: 107544685 3’-UTR; Transition Substitution
C__16025972_10 rs2515617 ABCA1 ch. 9: 107680915 Intron; Transition Substitution
C___2741040_10 rs2000069 ABCA1 ch. 9: 107635869 Intron; Transition Substitution
C__27093081_10 rs2472458 ABCA1 ch. 9: 107588015 Missense Mutation; Transition Substitution
C__15889845_10 rs2482432 (3’ near ABCA1
gene)
ch. 9: 107543172 3’ near gene; Intron; Transition Substitution
C__11266744_20 rs2740479 ABCA1 ch. 9: 107563437 Intron; Transition Substitution
(Continued )
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UTR or 3’-UTR regions) or were in linkage disequilibrium (LD) with some SNP located in
these putative gene regulatory regions and 7 SNPs were Missense Mutation (12,3%).
Genotyping
Genomic DNA from formalin fixated paraffin embedded (FFPE) tissue of the patients was
extracted using standard methods (QIAamp DNA FFPE Tissue Kit, Qiagen, Hilden, Ger-
many). DNA samples were genotyped for 57 selected SNPs located in 7 different genes impli-
cated in LM (Table 2) and whose expression have previously been associated with prognosis in
stage II CC patients [11, 12]. SNPs were screened using TaqMan1 OpenArray1 Genotyping
Plates (Applied Biosystems, Carlsbad, CA, USA) in a QuantStudio™ 12K Flex system according
to the manufacturer’s instructions. Genotype calling was obtained with the Taqman Genotyper
Software v1.3 (Applied Biosystems™).
Gene expression analysis
Formalin-Fixed, Paraffin-Embedded (FFPE) tumor samples from stage II and III CC patients
were deparaffinated using Deparaffinization Solution (Qiagen Gmbh, Hilden, Germany).
Afterwards, total RNA was purified from all samples using RNeasy FFPE Kit (Qiagen) follow-
ing manufacturer’s instructions and then was reverse transcribed by High Capacity cDNA
Archive Kit (Applied Biosystems, Carlsba, CA, USA) for 2 h at 37˚C, as described in detail in
previous studies [11, 12].
Gene expression data for the selected candidate genes (calculated with the 2–ΔCt method)
were previously analyzed in a HT-7900 Fast Real time PCR System using Taq-Man Low Density
Arrays (Applied Biosystems) and the gene expression data were normalized using the geometric
mean of the internal control genes GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) and
Table 2. (Continued)
Assay ID dbSNP Gene Symbol NCBI Assembly
Location
SNP Type
C___2741044_10 rs4743764 ABCA1 ch. 9: 107629104 Intron; Transition Substitution
C__16025975_10 rs2515614 ABCA1 ch. 9: 107684318 Intron; Transversion Substitution
C__11720848_10 rs2043664 (near ABCA1 gene) ch. 9: 107694245 Intergenic; Transition Substitution
C___9456257_10 rs1800977 ABCA1 ch. 9: 107690450 5’-UTR; Transition Substitution
C__11720790_1_ rs2065412 ABCA1 ch. 9: 107598740 Intron; Transition Substitution
C__16061836_10 rs2740484 ABCA1 ch. 9: 107551180 Intron; Transition Substitution
C___2960434_10 rs3847304 ABCA1 ch. 9: 107655848 Intron; Transition Substitution
C___8783836_10 rs3847305 ABCA1 ch. 9: 107657253 Intron; Transversion Substitution
C__11720774_10 rs2066720 ABCA1 ch. 9: 107554069 Intron; Transition Substitution
C__11266782_10 rs4743763 ABCA1 ch. 9: 107593182 Intron; Transversion Substitution
C___2741003_10 rs2575876 ABCA1 ch. 9: 107665739 Intron; Transition Substitution
C__27301445_10 rs3130284 AGPAT1 Chr.6: 32140487 Intron; Transition Substitution
C__27462316_10 rs3130283 AGPAT1 Chr.6: 32138545 Intron; Transversion Substitution
C___8847986_20 rs1061807 AGPAT1 Chr.6: 32136838 3’-UTR; Transition Substitution
"SNP type" in bold indicates nonsynonymous mutation or functional SNPs (located in putative gene regulatory region).
APOA2, apolipoprotein A-II; APOC1, apolipoprotein C-I; APOC2, apolipoprotein C-II; SCD, stearoyl-CoA desaturase (delta-9-desaturase); ACSL1, acyl-
CoA synthetase long-chain family member 1; ABCA1, ATP-binding cassette sub-family A member 1; AGPAT1, 1-acylglycerol-3-phosphate O-
acyltransferase 1; ch., chromosome; LD, Linkage disequilibrium; UTR, untranslated region.
doi:10.1371/journal.pone.0168423.t002
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B2M (Beta-2 microglobulin) using Real time StatMiner software (Integromics1 Inc., Madison,
WI, USA) as previously described [11, 12].
Statistical analysis
Genotype data for the investigated 57 SNPs in 7 candidate genes were obtained as described in
“genotyping” section. After Data Quality control and Quality Assurance (QC/QA) process we
excluded 19 SNPs that met any of following criteria: minor allele frequency (MAF) < 5%,
Hardy-Weinberg equilibrium (HWE) P-value < 0.0001 or percentage of missing data > 5%.
Therefore, 38 out of the 57 SNPs were selected, categorized by genotype (homozygote minor
allele, heterozygote and homozygote major allele) and checked for additive, dominant and
recessive model.
Two-tailed Pearson and Fisher exact tests were used to compare genotype distributions or
allele frequencies. Bonferroni corrections for multiple comparisons were performed based in
the number of selected SNPs after QC/QA process.
In order to assess the prognostic value of polymorphisms, genotypes of each polymorphism
were tested for association with DFS using univariate Cox-regression analysis, expressed as the
hazard ratio (HR) with 95% confidence intervals (CI). To calculate the effect on survival with
adjustment for potential confounding factors, a multivariate Cox-regression analysis was used
including only variables that were significant (p<005) in the univariate analysis of the clinical
data (S1 Table). DFS was defined as the time from surgery until the first documented tumor
recurrence or death. Overall survival was defined as the time from surgery until death. The
Kaplan–Meier method was used to estimate the survival probabilities, and the log-rank test
was used to test differences between subgroups. Haploview 4.2 software [15] was used to esti-
mate the linkage disequilibrium between the different SNPs.
To evaluate the association between ACSL1 and SCD gene expression level and the different
genotypes from the diverse models of inheritance for ACSL1 rs8086 and SCD rs522951 SNPs, a
non-parametric Kruskal-Wallis (KW) test and Analysis of Variance test (ANOVA) was per-
formed. Expression data of ACSL1 and SCD genes (calculated with the 2–ΔCt method) were pre-
viously analyzed and presented in Vargas et al., 2015 [11].
All statistical calculations were carried out using the R statistical software version 2.15
(www.r-project.org). P values<0.05 were considered significant, and all tests were two sided.
Results
Analysis of genetic variants within LM-related genes in CC patients
We aim to analyze the impact of 57 SNPs in 7 LM-related genes (whose expression have previ-
ously been associated with worse clinical outcome in stage II CC patients [11, 12]) on DFS in
284 CC patients (Table 2).
We found that among the SNPs selected after QC/QA process, only two genetic variants
were associated with clinical outcome of the patients, precisely one in Acyl-CoA Synthetase
Long Chain Family member 1 (ACSL1) and the other in the Stearoyl-Coa Desaturase gene
(SCD). Thus, T/T genotype for rs8086 (ACSL1 gene) in the recessive model of inheritance (HR
3.02; 95% CI 1.66–5.49; p = 0.001) and C/C genotype for rs522951 (SCD gene) in the dominant
model (HR 0.45; 95% CI 0.28–0.71; p = 0.001) were significantly associated with the clinical
outcome of stage II and III CC patients (Table 3).
The Kaplan Meier survival curves and the log-rank test also showed the association between
DFS and rs8086 (p<0.001) and rs522951 (p<0.001) (Fig 1).
ACSL1 Variant to Predict Colon Cancer Prognosis
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SCD genetic variant identifies CC patients with high risk of relapse
As mentioned above, C/C genotype for rs522951 (SCD gene) in the dominant model was asso-
ciated with the clinical outcome of CC patients (Fig 1). In the Multivariate Cox Regression
analysis, a trend of C/C genotype for rs522951 (p = 0.06; Table 3) with short DFS was observed,
indicating that patients carrying the SCD rs522951 C/G + G/G genotype had significantly
increased DFS compared with patients carrying the C/C genotype. The C/C genotype for
rs522951 (24% and 30% for stage II and III respectively, S2 Table) showed more than two-fold
higher risk of relapse that patients carrying the C/G + G/G genotype (HR 2.18; 95% CI 1.36–
3.5; p = 0.065 (inverse value of HR 0.46; 95% CI 0.29–0.73; p = 0.065)) (Table 3).
Thus, 3-year DFS in patients carrying the “risk genotype” for rs522951 SNP (C/C) was 63%
(95%CI: 0.528–0.752) compared with 82% (0.767–0.873) in patients with C/G + G/G genotype
(in the dominant model of inheritance).
Table 3. Multivariate Cox Regression analyses for DFS of different genetic models of inheritance for rs8086 (ACSL1) and rs522951 (SCD) SNPs in
stage II and III CC patients.
Bonferroni corrections for multiple comparisons# Adjusted for clinical variables*
SNP reference Model HR p-value Adjusted p-value HR p-value Adjusted p-value
rs8086 Additive 1.67 (1.16–2.39) 0.006 0.236 1.67 (1.16–2.42) 0.007 0.251
Dominant 1.43 (0.89–2.3) 0.134 1 1.42 (0.87–2.3) 0.151 1
Recessive 3.02 (1.66–5.49) 0.001 0.053 3.08 (1.69–5.63) 0.001 0.046
rs522951 Additive 0.67 (0.47–0.95) 0.024 0.920 0.67 (0.47–0.95) 0.022 0.817
Dominant 0.45 (0.28–0.71) 0.001 0.042 0.46 (0.29–0.73) 0.002 0.065
Recessive 0.99 (0.56–1.74) 0.967 1.000 0.91 (0.51–1.61) 0.741 1.000
#Adjustment for Bonferroni method was used in the multiple comparisons.
*Multivariate Cox Regression analyses were adjusted for age>70, pT category, vascular invasion, neuronal invasion and peritoneal perforation or
obstruction.
doi:10.1371/journal.pone.0168423.t003
Fig 1. Kaplan-Meier curve of ACSL1 SNP rs8086 and SCD SNP rs522951 on DFS for stage II and III CC patients in a recessive and
dominant model of inheritance, respectively. P-value was calculated by Log-rank test.
doi:10.1371/journal.pone.0168423.g001
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In addition, since SCD over-expression has been associated with tumor progression and
early-stage CC patient relapse[11, 16], we investigated whether rs522951 polymorphism corre-
lated with gene expression levels of SCD in a subsample of 209 stage II/III CC patients (140
and 69 stage II and III respectively) in which gene expression data was available due to enough
amount of sample for DNA and RNA extraction, and gene expression levels had been previ-
ously determined [11]. As expected by its intronic localization, results showed no correlation
between rs522951 genotype and SCD gene expression (Table 4; Fig 2).
Finally, in order to determine whether this genetic variant was a tumor-specific polymor-
phism (somatic mutation) or if by contrast was a germline polymorphism of the patient,
and therefore putatively traceable in plasma or saliva, we genotyped for rs522951 40 healthy
colon samples obtained from tissues adjacent to tumors from these patients. All tumor sam-
ples analyzed (100%) showed the same genotype for rs522951 that its respective adjacent
CC sample.
ACSL1 rs8086 genetic variant is associated with worse clinical outcome
of CC patients
On the other hand, T/T genotype for rs8086 (ACSL1 gene) in the recessive model of inheri-
tance was also found associated with DFS of the patients (HR 3.02; 95% CI 1.66–5.49;
p = 0.001) (Fig 1). After adjusting for multiple comparisons and clinical risk factors, the statis-
tically significant association for rs8086 polymorphism remained significant (p<0.05). The
adjusted HR for the association between rs8086 genotype (for the recessive model of inheri-
tance) and DFS was 3.08 (95% CI 1.69–5.63, p = 0.046) (Table 3), indicating that patients car-
rying the ACSL1 rs8086 T/T genotype had significantly decreased DFS compared with patients
carrying the C/T + C/C genotype, with 3-fold higher risk of relapse.
Table 4. Association between ACSL1 and SCD gene expression level and the different genotypes from the diverse models of inheritance for
ACSL1 rs8086 and SCD rs522951 SNPs in stage II and III CC patients.
SNP reference Model Genotype N Mean Median SD p-value (KW) p-value (Anova)
rs8086 Additive C/C 90 2.37 1.6 3.22 0.047 0.019
C/T 103 3.73 2.09 6.9
T/T 17 5.34 2.79 5.43
Dominant C/C 90 2.37 1.6 3.22 0.03 0.039
C/T + T/T 120 3.96 2.15 6.71
Recessive C/C + C/T 193 3.09 1.76 5.53 0.091 0.109
T/T 17 5.34 2.79 5.43
rs522951 Additive C/C 55 5.85 4.91 5.63 0.602 0.983
C/G 111 6.37 4.78 5.55
G/G 43 5.81 4.14 5.86
Dominant C/C 55 5.85 4.91 5.63 0.791 0.687
C/G + G/G 154 6.21 4.65 5.62
Recessive C/C + C/G 166 6.2 4.85 5.56 0.398 0.688
G/G 43 5.81 4.14 5.86
The reported p-values correspond to non-parametric Kruskal-Wallis (KW) test and Analysis of Variance test (ANOVA).
Mean and Median of gene expression values for ACSL1 and SCD genes are shown. The quantification of gene expression levels were analyzed in a
previously published manuscript (Vargas et al., 2015). The gene expression data were normalized using the geometric mean of the internal control genes
GAPDH and B2M.
N, number of cases with each genotype; SD, standard deviation.
doi:10.1371/journal.pone.0168423.t004
ACSL1 Variant to Predict Colon Cancer Prognosis
PLOS ONE | DOI:10.1371/journal.pone.0168423 December 19, 2016 9 / 15
Thus, 3-year DFS in patients carrying the “risk genotype” for rs8086 SNP (T/T) was 54.5%
(95%CI: 0.372–0.799) compared with 78.5% (0.736–0.837) in patients with C/T + C/C geno-
type (in the recessive model of inheritance).
Additionally, genotype for rs8086 polymorphism was analyzed in 40 samples of healthy
colon tissues that were obtained from apparently healthy tissues adjacent to tumors from these
patients. 40 out of the 40 healthy tissue samples analyzed (100%) had the same genotype for
rs8086 that its respective CC sample.
Finally, in the same manner as rs522951, we investigated whether rs8086 polymorphism cor-
related with gene expression level of ACSL1. Genotype-gene expression association study was
carried out in a subsample of 210 stage II/III CC patients (141 stage II and 69 stage III CC
patients) where gene expression levels of ACSL1 had been previously determined[11]. The
rs8086 SNP showed different ACSL1 gene expression level according to the genotype in each
and every model of inheritance (Table 4; Fig 2). In the additive model of inheritance for rs8086,
patients carrying C/C genotype had lower ACSL1 mRNA levels (mean = 2.37; SD = 3.22) com-
pared with C/T (mean = 3.73; SD = 6.9) and T/T genotype (mean = 5.34; SD = 5.43) with statis-
tically significant differences (p-value KW test = 0.047; p-value ANOVA = 0.019). In the
Fig 2. Box plots of the association between gene expression level for ACSL1 and genotype for rs8086 SNP located on the 3’-UTR
region. The box plots show how the ACSL1 expression values are distributed for each genotype from the Additive, Dominant and Recessive
model of inheritance for ACSL1 rs8086 SNP in stage II and III CC patients. The p-values were calculated using the non-parametric Krustal-
Wallis and Mann-Whitney tests, respectively. The line within the box indicate the median of level expression. The gene expression data were
normalized using the geometric mean of the internal control genes GAPDH and B2M.
doi:10.1371/journal.pone.0168423.g002
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dominant model, patients with C/C genotype had lower ACSL1 mRNA levels (mean = 2.37;
SD = 3.22) than those with C/T + T/T genotype (mean = 3.96; SD = 6.71) with statistically sig-
nificant differences (p-value KW test = 0.03; p-value ANOVA = 0.039). Finally, in the recessive
model the C/C + C/T genotype (mean = 3.09; SD = 5.53) presented the lowest ACSL1 mRNA
levels compared with T/T genotype (mean = 5.34; SD = 5.43) with a trend (p-value KW test =
0.091; p-value ANOVA = 0.109).
Discussion
Several lines of evidence indicate that LM plays a crucial role in carcinogenesis [11, 12, 17].
Accordingly, expression levels of several related genes have been found to display prognostic
and predictive value in CC patients [11, 12, 18].
In order to analyze whether genetic variants in these genes might be mediating this clinical
association, we tested whether 57 tagging polymorphisms (including functional variations)
located in 7 different LM-related genes previously associated with prognosis predict DFS in
284 patients with stage II/III CC. In addition, we evaluated whether different genotypes of the
functional polymorphisms correlated with levels of mRNA expression of the respective genes.
With respect to the analysis of the influence of the 57 analyzed SNPs on the DFS, the results
showed a robust association for rs8086 and rs522951 (Table 3; Fig 1) between DFS of the
patients and genotype for these polymorphisms within ACSL1 and SCD respectively, genes
that codify for two enzymes that have been recently described as a LM driving-force in colon
cancer progression [10].
In the multivariate model (adjusting for clinical risk factors and multiple comparisons),
only rs8086 confirmed the statistically significant association between genotype (for the reces-
sive model of inheritance) and DFS (Table 3), indicating that patients carrying the ACSL1
rs8086 T/T genotype had significantly decreased DFS compared with patients carrying the C/
T + C/C genotype, with 3-fold higher risk of relapse. Afterwards, in order to assess whether
rs8086 and rs522951 were a tumor-specific polymorphisms or by contrast a germline polymor-
phisms in these CC patients, we analyzed the genotype for both polymorphisms in 40 samples
of healthy colon tissues adjacent to tumors. The results showed that 100% of the samples had
the same genotype in both, healthy and tumor samples for rs8086 and rs522951, indicating
that rs8086 as well rs522951 are germline polymorphisms not specific of the tumor. These data
is of special relevance because if these results are further confirmed in validation cohorts,
rs8086 could be used as non-invasive biomarker of prognosis in stage II/III CC patients,
whose genomic DNA could be extracted from buccal epithelial cells in a non-invasive and sin-
gle manner. In this sense, further subgroup analysis was performed to confirm whether both
stages showed similar performance. As it is shown in S1 Fig, despite reducing the number of
samples included in the stratified analysis, in both stages these genetic variants were associated
with worse clinical outcome, with increased significance in stage II accordingly with previous
studies of the group (10–11). In addition, this analysis showed also association between these
genetic variants and worse clinical outcome in patients treated with chemotherapy and a trend
in those without treatment (S2 Fig), in which the number of patients is low as it usually found
in clinical practice, contributing in part to the lack of statistical significance in this last case.
In addition, since rs8086 was a functional polymorphism located in the 3’-UTR region of
ACSL1 gene, we aim to evaluate whether rs8086 genotype could be correlated with ACSL1
mRNA level and influence the prognosis of these CC patients according to the data previously
obtained [11]. Hence, genotype-gene expression level association in a subsample of 210 stage
II/III CC patients was carried out and the results showed that rs8086 exhibited different
ACSL1 gene expression level depending on rs8086 genotype for all model of inheritance
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(Table 4; Fig 2), highlighting that the decrease of the ACSL1 mRNA levels were directly pro-
portional to the number of C allele.
In summary, in this study T/T genotype for rs8086 is associated with worse clinical out-
come acting as a “risk genotype” in these CC patients and simultaneously correlates with high
ACSL1 mRNA levels, which in turn had previously been associated also with worse clinical
outcome in these patients [11] probably mediated by the induction of an invasive phenotype
[10].
To date, 50 SNPs located in 40 loci have been associated with the risk of CRC by genome-
wide association studies (GWASs) [2] and recent evidences indicate a potential prognostic and
predictive value in CC for polymorphisms in genes involved in a variety of cellular process
such as cell cycle control [19], inflammation [2, 20, 21], Hedgehog signaling pathway [14],
tight junction [22], DNA repair or drug metabolism and drug resistance [23–26]. In the con-
text of LM, a polymorphism in ApoE gene has been associated with CRC risk and prognosis in
a gender-dependent manner [27]. However, to our knowledge, this is the first report suggest-
ing a relationship between ACSL1 polymorphism and clinical outcome in stage II/III patients
with CC.
ACSL1 is an isozyme of Acyl-CoA synthetase (ACSL) family, which catalyzes the conversion
of long chain fatty acids to acyl-CoA, which is critical for phospholipid and triglyceride synthe-
sis, lipid modification of proteins as well as for fatty acid β-oxidation. Due to its relevant func-
tion in metabolic regulation, it has been recently shown to display an important role in cancer
cell survival, apoptosis inhibition and epithelial-mesenchymal transition [10, 11, 28]. Given
the role of ACSL1 in carcinogenesis and the influence of genetic polymorphisms in regulation
of gene expression and function, it is inferred that polymorphisms in this gene might exert an
influence on cancer susceptibility and progression. Furthermore, we have recently reported
that this enzyme constitutes a promising therapeutic target for CC therapy [10]. These findings
suggest that rs8086 ACSL1 polymorphism may serve as a useful prognostic biomarker, but due
to the strong evidence about the biological significance of this gene and the rather limited
number of cases in our study, further independent studies are needed to evaluate the signifi-
cance of our findings in the clinic. Moreover, and related to the potential clinical application
of this polymorphism as a non-invasive biomarker, an extensive and comparative genotyping
analysis for rs8086 of genomic DNA extracted from buccal epithelial cells (in saliva) or blood
cells (in plasma) compared to FFPE tumor samples from stage II and III CC patients are still
needed.
In conclusion, our study identified a genetic variant in the 3’-UTR region of ACSL1 gene
(rs8086) that may play a significant role in predicting outcomes of stage II/III patients with
CC, so that patients with T/T genotype had a significantly higher risk of tumor recurrence
than those carrying at least one C allele. The molecular mechanisms by which rs8086 ACSL1
polymorphism affects tumor behavior and recurrence are under investigation. Since rs8086
ACSL1 polymorphism is located at 3´-UTR region, and the SNP functional prediction tool
(F-SNP) has shown that a single nucleotide change from C to T may alter miRNAs binding
sites in this gene, modulation of transcription has been suggested. Consistent with this sugges-
tion, additional studies are needed to better elucidate the mechanisms underlying these puta-
tive associations. Furthermore, taking into consideration the reported cooperative network of
ACSL1, ACSL4 and SCD and its role in the progression of colorectal cancer, the future direc-
tion of the current research will be to test the mutation status of all three genes together and
examine the putative association with the expression level of these genes and with clinical out-
come in stage II/III CC patients.
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Supporting Information
S1 Fig. Kaplan-Meier curve of ACSL1 SNP rs8086 and SCD SNP rs522951 on DFS stratified
by stage (stage II vs III). P-value was calculated by Log-rank test.
(TIF)
S2 Fig. Kaplan-Meier curve of ACSL1 SNP rs8086 and SCD SNP rs522951 on DFS stratified
by chemotherapy (patients with chemotherapy vs patients without chemotherapy). P-value
was calculated by Log-rank test.
(TIF)
S1 Table. Univariate cox regression analysis for Disease-free survival of the clinical vari-
ables in stage II and III CC patients. HR (95% CI), hazard ratio and corresponding 95% con-
fidence interval from univariate cox proportional hazards analysis; P, p value from univariate
cox regression analysis.
(XLSX)
S2 Table. Genotype frequency for rs8086 (ACSL1) and rs522951 (SCD) SNPs in stage II
and III CC patients. N, number of cases in each genotype; %, percentage of cases in each
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